A once-in-a-decade chance to get rich by investing in FTSE 100 shares?

After lagging overseas stocks for over 10 years, our writer investigates whether FTSE 100 shares could be the smart place for his money today.

| More on:

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 index has attracted its fair share of criticism in recent years. Arguably, much of the flak has been warranted.

Recent research from Goldman Sachs has revealed that the Footsie delivered a 6% total annual return over the past decade. Compared to 8% for Europe’s Stoxx 50 and 13% for America’s S&P 500, Britain’s largest shares have been international laggards.

However, there are indications the tide could be turning for FTSE 100 stocks. Consequently, UK investors might consider looking closer to home for strong future returns. Here’s why.

A rare bargain opportunity

Using the 12-month forward price-to-earnings (P/E) ratio as a gauge, FTSE 100 shares look remarkably cheap relative to pricier stocks stateside.

UK shares trade at a 55% discount to their US counterparts. This gap is the widest it’s been since 1988 by a considerable margin. Value investors have good reasons to view today as a potential buying opportunity we haven’t seen for many, many years.

However, as a note of caution, this gulf has widened substantially since the 2016 Brexit vote and shows little sign of narrowing. At least for now.

Worryingly, UK-focused equity funds have suffered retail investor outflows for three years on the trot. There’s a risk Britain’s stock market malaise could continue for a while yet. Restoring investor confidence is far from guaranteed.

The stagnation of Japanese stocks for 30 years, starting in the early 1990s, is evidence of how long the suffering can persist in developed equity markets.

Where next for UK shares?

That said, the comparison with Japan only goes so far. Its ‘Lost Decades’ followed the bursting of a huge asset price bubble amid periods of monetary tightening.

By contrast, the UK seems to be heading in the other direction today. Despite holding interest rates at 5% in the last Monetary Policy Committee meeting, the Bank of England indicated it’s on a trajectory towards further easing over the coming months.

Governor Andrew Bailey said interest rates are “now gradually on the path down“. Additional rate cuts could spark some much-needed growth for FTSE 100 share prices.

In this context, I can see the logic behind the latest Goldman Sachs FTSE 100 forecast. The bank predicts the index will surge to 8,800 points within 12 months. As I write, the Footsie’s hovering around the 8,233 level.

A FTSE 100 stock to consider

Identifying which shares in the index appear deeply undervalued can be very lucrative over the long run. One candidate to consider buying is pharma giant GSK (LSE:GSK).

The stock’s forward P/E of 8.64 is well below the average for other companies in the industry and the index as a whole.

GSK also stacks up well on other valuation metrics. A price-to-book (P/B) ratio of 4.4 and price-to-sales (P/S) ratio of 1.8 both indicate a potential bargain.

Granted, long-running litigation concerning the firm’s Zantac heartburn medication continues to cloud the growth outlook. Disappointing sales for the company’s shingles and respiratory syncytial virus (RSV) vaccines are also a cause for concern.

But, I’m pleased to see other areas of the business, including cancer, HIV, and other speciality medicines, are growing fast. The group’s overall revenue performance exceeded expectations in Q2 and FY24 guidance has been upgraded.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Charlie Carman has positions in Goldman Sachs Group and GSK. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

Just released: October’s higher-risk, high-reward stock recommendation [PREMIUM PICKS]

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.

Read more »

A Black father and daughter having breakfast at hotel restaurant
Investing Articles

2 household names quietly thrashing the FTSE 100

Paul Summers takes a closer look at two FTSE 100 stocks that have soared despite recent economic headwinds. Will they…

Read more »

Investing Articles

A FTSE 250 share and an ETF I’d buy for a second income

I'm looking for ways to make a healthy passive income and I think this stock and this exchange-traded fund (ETF)…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

3 reasons why I’m avoiding Rolls-Royce shares like the plague!

Rolls-Royce shares trade on a meaty price-to-earnings (P/E) ratio of 30 times. Royston Wild thinks this leaves them in danger…

Read more »

Investing Articles

After crashing another 15% today is this FTSE blue-chip now the best share to buy today?

Harvey Jones has been watching FTSE 100 gambling stock Entain for months and is now wondering whether it's the best…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Here’s what Warren Buffett says is ‘the best way to minimise risk’ (it’s not buying the S&P 500)

What should investors do to try and avoid losing money? Warren Buffett has an answer that doesn’t involve buying an…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

2 cheap shares I wouldn’t touch with a bargepole in today’s stock market

These FTSE 100 and small-cap stocks are on sale right now. But Royston Wild believes these cheap UK shares may…

Read more »

Investing Articles

Here’s the growth forecast for Greggs shares through to 2027!

City analysts expect the UK's leading food-on-the-go retailer to continue growing. But would this writer buy Greggs shares today?

Read more »